Cornerstone Pharmaceuticals, Inc. Lead Compound CPI-613 Demonstrates Ability To Disrupt Growth Of Cancer Cells
Published: Mar 13, 2014
CRANBURY, N.J., March 12, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that its first-in-class cancer metabolism targeted therapeutic, CPI-613, demonstrated the ability to inhibit tumor cell growth in the published studies. The research was conducted by Stony Brook University researchers and members of Cornerstone's cancer metabolism research team and Scientific Advisory Board, Paul M. Bingham, PhD, and Zuzana Zachar, PhD.
Help employers find you! Check out all the jobs and post your resume.